Entrada Therapeutics has released its financial results for the second quarter of 2025, which included important updates on its clinical programs for Duchenne muscular dystrophy (DMD).
Entrada have now began enrolling participants in the UK for their ELEVATE-44-201 and ELEVATE-45-201 studies, eligible to Duchenne muscular dystrophy (DMD) patients amenable to exon 44 and 45 skipping, respectively.
The company have also stated they expect to submit global regulatory filings for the phase 1/2 clinical studies in the UK and EU for their ENTR-601-50 (exon 50 amenable patients) in Q4 of 2025, and ENTR-601-51 (exon 51 amendable patients) in 2026.
If you have any questions or queries regarding the information presented in this article, please reach out to us at info@actionduchenne.org
